Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blind loop syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Blind loop syndrome. Displaying page 1 of 1.
    EudraCT Number: 2007-001407-37 Sponsor Protocol Number: CKI- 301 Start Date*: 2007-06-20
    Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
    Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f...
    Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) HU (Completed) IT (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001637-18 Sponsor Protocol Number: CKI- 302 Start Date*: 2006-11-13
    Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
    Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f...
    Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) CZ (Completed) BE (Completed) DK (Prematurely Ended) GB (Completed) HU (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000780-48 Sponsor Protocol Number: J3E-MC-EZDB Start Date*: 2022-11-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HF...
    Medical condition: HFpEF (heart failure with preserved ejection fraction)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000042-30 Sponsor Protocol Number: GS-US-372-1234 Start Date*: 2015-05-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome
    Medical condition: Subjects with an established diagnosis of LQT3.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10007541 - Cardiac disorders 10024803 Long QT syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003573-32 Sponsor Protocol Number: 2022/ABM/01/00027 Start Date*: 2023-12-28
    Sponsor Name:Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the effect of allopurinol on the risk of cardiovascular events in patients at high and very high cardiovascular risk, including the ...
    Medical condition: hyperuricemia, hypertension, ischemic stroke, intracerebral haemorrhage, TIA, heart failure, peripheral arterial disease, atrial fibrillation, diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020907 Hyperuricemia LLT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    20.0 10007541 - Cardiac disorders 10019279 Heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    27.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004917-15 Sponsor Protocol Number: RebOx Start Date*: 2020-04-22
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Crossover, Double-blind, Phase 2 Study of a Fixed Dose Combination of Reboxetine\Oxybutynin (AD128) Versus Placebo in Obstructive Sleep Apnea (RebOx)
    Medical condition: Obstructive Sleep Apnea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10040978 Sleep apnoeas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001467-36 Sponsor Protocol Number: FER-CARS-06 Start Date*: 2017-02-02
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Randomised, Double-blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart F...
    Medical condition: Acute heart failure with iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    20.0 100000011689 10000803 Acute heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) PL (Completed) HR (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001579-35 Sponsor Protocol Number: KBP5074-2-001 Start Date*: 2019-08-07
    Sponsor Name:KBP BioSciences Co., Ltd.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients with Moderate-to-Severe Chronic Kidney Disea...
    Medical condition: Moderate to Severe Chronic Kidney Disease and uncontrolled hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 100000004866 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001698-25 Sponsor Protocol Number: LIVERHOPE_EFFICACY Start Date*: 2018-07-24
    Sponsor Name:IDIBAPS
    Full Title: Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical t...
    Medical condition: Patients with decompensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009209 Cirrhosis bilary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 31 23:12:11 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA